**Supplementary file ‘Supplementary Table 3 Patient Characteristics of Neonates with Aberrant versus Normal Screening Results’**

**Title: Nationwide Evaluation of Congenital Hypothyroidism Screening during Neonatal Extracorporeal Membrane Oxygenation**

Authors: Lisette Leeuwen, MD1, Arno F.J. van Heijst, MD PhD2, Sanne Vijfhuize, MD1, Leonardus W.J.E. Beurskens, MD PhD1, Gert Weijman, MD3, Dick Tibboel, MD PhD1, Erica L.T. van den Akker, MD PhD4, Hanneke IJsselstijn, MD PhD1

Journal name: Neonatology

**Supplementary Table 3 Patient Characteristics of Neonates with Aberrant versus Normal Screening Results**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Aberrant screening result  n=102 | Normal screening result  n=66 | p-value |
| Gestational age (weeks) | 39.9 (38.1-41.0) | 40.3 (38.3-41.2) | 0.37 |
| Birth weight (grams) | 3311±611 | 3310±694 | 1.00 |
| Male | 66 (64.7%) | 33 (50.0%) | 0.06 |
| Primary diagnosis  Meconium aspiration syndrome  Congenital diaphragmatic hernia  Sepsis  Persistent pulmonary hypertension  Other1 | 36 (35.3%)  31 (30.4%)  11 (10.8%)  18 (17.6%)  6 (5.9%) | 31 (47.0%)  15 (22.7%)  8 (12.1%)  6 (9.1%)  6 (9.1%) | 0.30 |
| Age at start ECMO therapy (day of life) | 3 (2-4) | 2 (1-3) | 0.06 |
| Duration of ECMO therapy (days) | 6 (4-8) | 5 (3-6) | 0.001 |
| PRISM III score (first 24 hours of PICU admission) | 18±6.4 | 17±7.2 | 0.32 |
| Age at CH screening (day of life) | 4 (4-5) | 4 (4-5) | 0.32 |
| PELOD-2 score (24 hours prior to CH screening) | 6 (6-8) | 6 (5-7) | 0.02 |

Data are expressed as mean±SD, median (interquartile range) or number (percentage), as appropriate.

1 Other: congenital heart disease, congenital cystic adenomatoid malformation, recurrent pneumothoraces, infant respiratory distress syndrome in combination with pneumothorax, meconium peritonitis, respiratory failure of unknown cause.

CH=congenital hypothyroidism; ECMO=extracorporeal membrane oxygenation; PELOD-2=Pediatric Logistic Organ Dysfunction-2; PICU=Pediatric Intensive Care Unit; PRISM III=Pediatric Risk of Mortality III.